Evolv Technologies Holdings, Inc.

(a) Disclosure in lieu of reporting on a Current Report on Form 8-K.

None.

(b) Material changes to the procedures by which security holders may recommend nominees to the board of directors.

None.

(c) Insider trading arrangements.

During the quarter ended June 30, 2025, the following director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted, modified, orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

•On June 12, 2025, Anil Chitkara, Co-Founder and Chief Growth Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of 360,000 shares of the Company’s common stock underlying 360,000 stock options. The trading arrangement is scheduled to expire on the earlier of March 31, 2026 or the date that all transactions under the trading arrangement are completed.

•On June 12, 2025, Michael Ellenbogen, Co-Founder, Chief Innovation Officer, and Director, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of 888,202 shares of the Company’s common stock underlying 888,202 stock options and net shares of the Company's common stock underlying 174,664 restricted stock units. The trading arrangement is scheduled to expire on the earlier of September 14, 2026 or the date that all transactions under the trading arrangement are completed.